Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover

36:41 | Feb 4th, 2016

Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.